The Anoikis-related Gene Signature Predicts Survival Accurately in Colon Adenocarcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2023 Aug 25

PMID 37626132

Authors

Gunchu Hu

Jian Li

Yi Zeng

Lixin Liu

Zhuowen Yu

XiaoYan Qi

Kuijie Liu

Hongliang Yao

Affiliations

Soon will be listed here.

Abstract

Colon adenocarcinoma (COAD) is a serious public health problem, the third most common cancer and the second most deadly cancer in the world. About 9.4% of cancer-related deaths in 2020 were due to COAD. Anoikis is a specialized form of programmed cell death that plays an important role in tumor invasion and metastasis. The presence of anti-anoikis factors is associated with tumor aggressiveness and drug resistance. Various bioinformatic methods, such as differential expression analysis, and functional annotation analysis, machine learning, were used in this study. RNA-sequencing and clinical data from COAD patients were obtained from the Gene expression omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Construction of a prognostic nomogram for predicting overall survival (OS) using multivariate analysis and Lasso-Cox regression. Immunohistochemistry (IHC) was our method of validating the expression of seven genes that are linked to anoikis in COAD. We identified seven anoikis-related genes as predictors of COAD survival and prognosis, and confirmed their accuracy in predicting colon adenocarcinoma prognosis by KM survival curves and ROC curves. A seven-gene risk score consisting of NAT1, CDC25C, ATP2A3, MMP3, EEF1A2, PBK, and TIMP1 showed strong prognostic value. Meanwhile, we made a nomogram to predict the survival rate of COAD patients. The immune infiltration assay showed T cells. CD4 memory. Rest and macrophages. M0 has a higher proportion in COAD, and 11 genes related to tumor immunity are important. GDSC2-based drug susceptibility analysis showed that 6 out of 198 drugs were significant in COAD. Anoikis-related genes have potential value in predicting the prognosis of COAD and provide clues for developing new therapeutic strategies for COAD. Immune infiltration and drug susceptibility results provide important clues for finding new personalized treatment options for COAD. These findings also suggest possible mechanisms that may affect prognosis. These results are the starting point for planning individualized treatment and managing patient outcomes.

Citing Articles

Assessment of prognosis and responsiveness to immunotherapy in colorectal cancer patients based on the level of immune cell infiltration.

Liao K, Zhu M, Guo L, Gao Z, Cheng J, Sun B Front Immunol. 2025; 16:1514238.

PMID: 39963131 PMC: 11830669. DOI: 10.3389/fimmu.2025.1514238.

Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets.

Sehrawat U Int J Mol Sci. 2024; 25(19).

PMID: 39409166 PMC: 11477148. DOI: 10.3390/ijms251910835.

Feng F, Chu Y, Yao Y, Xu B, Song Q Heliyon. 2024; 10(10):e31202.

PMID: 38803953 PMC: 11128934. DOI: 10.1016/j.heliyon.2024.e31202.

Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading.

Naponelli V, Rocchetti M, Mangieri D Int J Mol Sci. 2024; 25(10).

PMID: 38791608 PMC: 11122459. DOI: 10.3390/ijms25105569.

Identification and validation of a novel six-gene signature based on mucinous adenocarcinoma-related gene molecular typing in colorectal cancer.

Man Y, Xin D, Ji Y, Liu Y, Kou L, Jiang L Discov Oncol. 2024; 15(1):63.

PMID: 38443703 PMC: 10914658. DOI: 10.1007/s12672-024-00916-2.

References

Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

Kim H, Choi P, Kim T, Kim Y, Song B, Park Y . Ginsenosides Rk1 and Rg5 inhibit transforming growth factor-β1-induced epithelial-mesenchymal transition and suppress migration, invasion, anoikis resistance, and development of stem-like features in lung cancer. J Ginseng Res. 2021; 45(1):134-148. PMC: 7790904. DOI: 10.1016/j.jgr.2020.02.005. View

Wu C, Lyu J, Yang E, Liu Y, Zhang B, Shim J . Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun. 2018; 9(1):3212. PMC: 6086874. DOI: 10.1038/s41467-018-05694-4. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Tang C, Qiu S, Mou W, Xu J, Wang P . Excessive activation of HOXB13/PIMREG axis promotes hepatocellular carcinoma progression and drug resistance. Biochem Biophys Res Commun. 2022; 623:81-88. DOI: 10.1016/j.bbrc.2022.07.066. View

Corbet C, Bastien E, Santiago de Jesus J, Dierge E, Martherus R, Vander Linden C . TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020; 11(1):454. PMC: 6978517. DOI: 10.1038/s41467-019-14262-3. View

Yu G, Wang L, Yan G, He Q . DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015; 31(4):608-9. DOI: 10.1093/bioinformatics/btu684. View

Wheeler L, Watson Z, Qamar L, Yamamoto T, Post M, Berning A . CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018; 7(11):92. PMC: 6255906. DOI: 10.1038/s41389-018-0103-1. View

10.

Kim Y, Koo K, Sung J, Yun U, Kim H . Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012; 2012:306879. PMC: 3296207. DOI: 10.1155/2012/306879. View

11.

Durinck S, Spellman P, Birney E, Huber W . Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009; 4(8):1184-91. PMC: 3159387. DOI: 10.1038/nprot.2009.97. View

12.

Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y . The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. Mol Cell. 2017; 69(1):87-99.e7. PMC: 5777230. DOI: 10.1016/j.molcel.2017.11.025. View

13.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

14.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

15.

Jin L, Chun J, Pan C, Alesi G, Li D, Magliocca K . Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene. 2017; 36(27):3797-3806. PMC: 5501759. DOI: 10.1038/onc.2017.6. View

16.

Han H, Sung J, Kim S, Yun U, Kim H, Jang E . Fibronectin regulates anoikis resistance via cell aggregate formation. Cancer Lett. 2021; 508:59-72. DOI: 10.1016/j.canlet.2021.03.011. View

17.

Joung E, Kim J, Yoon N, Maeng L, Kim J, Park S . Expression of Is Associated with Prognosis of Patients with Colon Adenocarcinoma. J Clin Med. 2019; 8(11). PMC: 6912729. DOI: 10.3390/jcm8111903. View

18.

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

19.

Zhi Z, Ouyang Z, Ren Y, Cheng Y, Liu P, Wen Y . Non-canonical phosphorylation of Bmf by p38 MAPK promotes its apoptotic activity in anoikis. Cell Death Differ. 2021; 29(2):323-336. PMC: 8817011. DOI: 10.1038/s41418-021-00855-3. View

20.

Maeser D, Gruener R, Huang R . oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021; 22(6). PMC: 8574972. DOI: 10.1093/bib/bbab260. View